NCT04884204 (SIMPly-CARE) is a NA clinical trial of Lee Symptom Scala in GVHD, Chronic, sponsored by Rigshospitalet, Denmark.

Who is sponsoring NCT04884204?

NCT04884204 is sponsored by Rigshospitalet, Denmark.

What drugs are being tested in NCT04884204?

Interventions in NCT04884204: Lee Symptom Scala.

What condition does NCT04884204 study?

NCT04884204 studies GVHD, Chronic, Hematological Malignancy.

Is NCT04884204 still recruiting?

NCT04884204 is currently completed. Last updated 28 November 2023.

Last reviewed 2023-11-28 · How we verify

NCT04884204: SIMPly-CARE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Systematic Symptom Identification With Disease Specific PROM to Assess Symptoms of Chronic GVHD in Outpatient Care in Patients Post HSCT

Completed NA Last updated 28 November 2023

What this trial tests

NA trial testing Lee Symptom Scala in GVHD, Chronic in 35 participants. Completed in 1 July 2023.

Timeline

30 April 2021

Primary endpoint
1 July 2023

1 July 2023

Quick facts

Lead sponsor	Rigshospitalet, Denmark
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	35
Start date	30 April 2021
Primary completion	1 July 2023
Estimated completion	1 July 2023
Sites	1 location across Denmark

Drugs / interventions tested

Lee Symptom Scala

Conditions studied

GVHD, Chronic — all drugs for GVHD, Chronic →
Hematological Malignancy — all drugs for Hematological Malignancy →

Sponsor

Rigshospitalet, Denmark

Who can join

18 and older, any sex, with GVHD, Chronic or Hematological Malignancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A two sited feasibility study to test the feasibility of systematic symptom identification with disease specific and clinically developed PROM (Lee Symptom Scale) longitudinally with a 12 month follow up in outpatient care in patients post HSCT to assess symptoms of chronic GVHD (n= 30).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for GVHD, Chronic

Currently open trials in the same condition.

NCT06462365 — Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) · Phase 1 · recruiting

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04884204 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
Last refreshed: 28 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04884204.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing